hydroxamic acid/inflammation

This application is the U.S. National Phase of International Application PCT/IT2004/000002 filed 7 Jan. 2004, which designated the U.S. PCT/IT2004/000002 claims priority to Italian Application No. MI2003A000025 filed 10 Jan. 2003. The entire content of these applications are incorporated herein by

This invention relates to novel heterocyclic compounds possessing 5-lipoxygenase/cyclooxygenase inhibitory and leukotriene antagonist activity, which are useful as anti-inflammatory and antiallergic agents. It is known that arachidonic acid (AA) is metabolized in mammals by two distinct pathways.

BACKGROUND OF THE INVENTION The standard synthesis for pyrazoles involves the reaction of a .beta..epsilon..tau..alpha.-dicarbonyl compound with a hydrazine under mild conditions. See A. R. Katritzky in "The Principles of Heterocyclic Chemistry", Academic Press, New York (1968) at page 139. When the

TECHNICAL FIELD The present invention relates to an oxazole derivative useful for inhibition of histone deacetylase. More specifically, the present invention relates to an oxazole hydroxamic acid derivative useful for inhibition of histone deacetylase and use thereof. BACKGROUND ART Histones are

FIELD OF THE INVENTION The present invention relates to a novel class of hydroxamic acid derivatives having a benzothiophene or thiophene backbone. The hydroxamic acid compounds can be used to treat cancer. The hydroxamic acid compounds can also inhibit histone deacetylase and are suitable for use

This invention relates to novel hydroxamic acid compounds which are useful as pharmaceuticals, e.g., in inhibiting matrix metalloproteinases such as collagenase, and in inhibiting TNF production, particularly for treatment of diseases or conditions mediated by over-production of or

FIELD OF INVENTION The present invention relates to acetylenic aryl sulfonate hydroxamic acids which act as inhibitors of TNF-.alpha. converting enzyme (TACE) and matrix metalloproteinases (MMP), to processes for the preparation of such compounds, and to pharmaceutical compositions comprising such

FIELD OF INVENTION The present invention relates to acetylenic aryl sulfonate hydroxamic acids which act as inhibitors of TNF-.alpha. converting enzyme (TACE) and matrix metalloproteinases (MMP), to processes for the preparation of such compounds, and to pharmaceutical compositions comprising such

FIELD OF THE INVENTION The present invention relates to small molecules which inhibit matrix metalloproteinases, and the production of tumor necrosis factor (TNF), pharmaceutical preparations containing them and to their use as pharmaceutical agents. BACKGROUND OF THE INVENTION There is now a body

The invention relates to arylsulfonamido-substituted hydroxamic acid derivatives, to processes and novel intermediates for their preparation, pharmaceutical compositions comprising said derivatives, pharmaceutical compositions comprising selective MMP2 inhibitors, the use of the hydroxamic acid

This application is 371 of PCT/EP00/07641 filed on Aug. 7, 2000, which claim benif of United Kingdom 9918684.3 filed on Aug. 9, 1999. The invention relates to arylsulfonamido-substituted hydroxamic acid derivatives, to processes and novel intermediates for their preparation, pharmaceutical

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to the hydroxamic acid derivatives subsituted by di-tert-butyl(hydroxy)phenylthio residue which may be useful as medicine. More particularly, it relates to the hydroxamic acid derivatives subsituted by

BACKGROUND OF THE INVENTION The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)

BACKGROUND OF THE INVENTION The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)

BACKGROUND OF THE INVENTION The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)